Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

A federal judge heard final arguments on Friday as to whether or not a mentally ill arson suspect should be forcibly medicated to try and make him competent to stand trial for a 2021 fire in ...

Can large national health plans make an impact in reducing prescribing of high-risk medications to people with Alzheimer's ...

The state auditor report found poor record keeping and a lack of therapy to accompany psychotropic medications.

Bristol Myers Squibb (BMS) witnessed the largest growth in market capitalisation of 24.6% to $105bn in Q3 2024, fuelled by ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...